You raised a pre-seed, you have four paying customers, and you're at $15K MRR. Not enough to be cashflow positive, but enough that a revenue-based financing provider has started calling.
The pitch lands cleanly: no dilution, no new board seat, capital now in exchange for a percentage of monthly revenue until a fixed repayment cap is hit. If you grow fast, you pay it back fast. If growth slows, the payments slow with it.
That's a real structure. But the math deserves careful reading. What looks like flexible growth capital can become the most expensive money you've raised.
How revenue-based financing works
A provider gives you capital — typically 3–6x your current MRR — in exchange for a percentage of your monthly revenue (usually 2–8%) until you've repaid 1.3x to 2.0x the original amount. The repayment multiplier is the total cap, and it's the number that determines whether the deal is reasonable.
A $150K advance at a 1.5x cap means you repay $225,000 total. At 5% of monthly revenue on a $15K MRR base, you're paying $750/month to start. The effective annualized interest rate on a deal like that often lands between 25% and 50%.
Compare that to equity at a $4M post-money pre-seed valuation: roughly 3–4% for $150K, with no repayment obligation. The right instrument depends entirely on your stage and trajectory.
When it makes sense
Predictable, growing MRR. The model takes a cut of revenue. Lumpy or seasonal revenue creates payment pressure in quiet months. Monthly recurring revenue from long-term contracts is the right profile.
Close to break-even. If $150K gets you from $15K to $25K MRR and then you're cashflow positive, revenue-based financing bridges that gap without raising a full priced round. Manageable when the repayment period is 12–18 months.
Defending against low-valuation dilution. If your valuation is still early, revenue-based financing lets you grow into better terms before taking institutional capital. The economics of giving up 15% at a low valuation to grow from $15K to $30K MRR are often worse than a short-term revenue share.
No venture backing yet. Venture debt typically requires existing venture investors. Revenue-based financing works with bootstrapped or lightly-capitalized companies that have consistent MRR.
When it doesn't make sense
Pre-revenue or unpredictable revenue. Revenue-based financing requires revenue. If you're not generating consistent MRR, you're not the right candidate.
Long sales cycles. If contracts take 6 months to close, your MRR is lumpy, and a 5% revenue share will create cash flow pressure in quiet months.
Two to four months from a priced round. Taking revenue-based financing now creates repayment obligations that complicate diligence without giving you meaningful runway benefit. Clean up the structure for the raise instead.
You need more than 6x MRR. Providers rarely advance beyond that threshold. Larger capital needs require a different instrument.
What to read carefully in the term sheet
The royalty rate and the repayment cap are the two variables that determine whether the deal is reasonable. A 1.35x cap at 4% revenue share is a materially different deal from a 2.0x cap at 8%. Run the math on your actual revenue trajectory before you sign.
Watch for minimum monthly payments. Some providers include a payment floor regardless of what you earn that month. This eliminates the flexible-with-your-growth benefit that makes the structure appealing.
Look at prepayment terms. Most deals let you pay off the remaining cap balance when you close an equity round. Some include prepayment penalties. If you expect to raise equity in the next 18 months, the prepayment structure matters.
Ask about renewal terms. Some providers offer additional advances once the first cap is repaid. Know whether you're borrowing to grow or borrowing to survive — those lead to different decisions about whether to renew.
The full menu at this stage
Before committing to revenue-based financing, check the alternatives. A SAFE at a reasonable cap is straightforward and carries no repayment obligation. If you have traction and a clear use of proceeds, investors who know the space will move quickly. Dilution is higher than revenue-based financing, but the structure is cleaner and there's no monthly payment.
Venture debt, if you've already raised a priced round, runs 8–12% annualized interest — significantly cheaper than most revenue-based financing structures. It requires existing venture backing, so it's not available to everyone.
Grants and non-dilutive programs exist in most industries: state economic development funds, SBIR grants for tech companies, industry-specific programs. Capital is rarely large, but $50–150K with no repayment obligation is worth an application before you borrow.
Revenue-based financing is a tool, not a strategy. When the math works for your stage and trajectory, it fills a specific gap. When it doesn't, there's no compelling reason to take expensive money because it was offered.
If you're evaluating capital options alongside a pre-seed raise and want a straight read on the tradeoffs, pitch us a note. We've seen this decision from both sides.